Free Trial

Acumen Pharmaceuticals Q1 2023 Earnings Report

Acumen Pharmaceuticals logo
$1.97 +0.01 (+0.51%)
(As of 08:13 AM ET)

Acumen Pharmaceuticals EPS Results

Actual EPS
-$0.28
Consensus EPS
-$0.33
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Acumen Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Acumen Pharmaceuticals Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

This drone stock is setting up to transform medical supply delivery (Ad)

Drone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.

Click here to see how a new partnership could catapult this drone suppliers' growth

Acumen Pharmaceuticals Earnings Headlines

Acumen Pharmaceuticals Advances Alzheimer’s Therapeutic
How to piss off your liberal friends… and profit from it
Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.
Q3 2024 Acumen Pharmaceuticals Inc Earnings Call
See More Acumen Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Acumen Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Acumen Pharmaceuticals and other key companies, straight to your email.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals (NASDAQ:ABOS), a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

View Acumen Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings